Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312538 | 0.87 | CCR1 (0.36) | SMN1; SMN2CYP1A2POLBNPC1RAB9A | |
| SCHEMBL13781597 | 0.81 | TP53 (0.43) | SMN1; SMN2CYP1A2ALDH1A1LMNANPC1 | |
| SCHEMBL4548424 | 0.77 | HCAR2 (0.43) | — | |
| SCHEMBL4548367 | 0.70 | CA12 (0.47) | SMN1; SMN2CYP1A2CA12CA1CA9 | |
| SCHEMBL14340914 | 0.69 | TP53 (0.44) | SMN1; SMN2CYP1A2ALDH1A1LMNANPC1 | |
| SCHEMBL13920697 | 0.69 | TP53 (0.53) | SMN1; SMN2CYP1A2ALDH1A1LMNANPC1 | |
| SCHEMBL4548430 | 0.68 | FFAR1 (0.56) | SMN1; SMN2ALDH1A1LMNAPOLBNPC1 | |
| SCHEMBL10312537 | 0.67 | CCR1 (0.43) | SMN1; SMN2CYP1A2ALDH1A1NPC1RAB9A | |
| SCHEMBL4548419 | 0.66 | MMP2 (0.43) | SMN1; SMN2NPC1RAB9AMMP2MMP8 | |
| SCHEMBL4548460 | 0.65 | HCAR2 (0.36) | SMN1; SMN2HTTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | SMN1; SMN2 4003/4885CYP1A2 586/4885CA12 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.